Systemic sclerosis & Raynaud's
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region
An erratum to this article was published (Rheumatology (Oxford), 1 Sep 2023 ↗)
Authors' conclusion
Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD.
Study context
- Population
- SSc patients in the EUSTAR database, clustered into seven geographical regions6,732 for survival analyses
- Participants
- 9,260 patients
- Exposure
- SSc-ILD across seven predetermined geographical regions
- Outcome
- Prevalence, phenotype, treatment and prognosis of SSc-ILD by region
Methodological detailsEUSTAR database, seven predetermined geographical regions
- EUSTAR database
- Seven predetermined geographical regions
Main finding
As reported in the abstract
Prevalence of SSc-ILD
- Prevalence of SSc-ILD in the overall population
- 50.2%
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| MMF prescribed at baseline in SSc-ILDAmerica (North and South) vs Asia and Oceania · across regions | America (North and South) 31.6% · Middle East 31.7% · Asia and Oceania 4.3% | P < 0.0001 |
| Survival rate at end of follow-up (highest regions) | America (North and South) 85.8% · Middle East 85.2% |
Original publication
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology (Oxford). Published 12 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →